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Prevention of Recurrent Systemic Embolism with
Anticoagulants in Patients with Rheumatic Heart Disease
Sudarsan Misra, M.D,* and Irwin J . Schatz, M.D,*

Results are reported of long-term anticoagulant
treatment in a group of 90
patients with rheumatic heart disease who had systemic embolism. Compared to
the reported incidence of recurrent systemic embolism in patients not given anticoagulant drugs, such therapy remarkably lowers the risk of such
occurrences.
Complications from this treatment in the reported patients were minimal.

of one or more episodes of previous
systemic embolism. None of this group
had prosthetic valve replacement.
There were 67 females and 23 males.
The age group and diagnosis are shown
in Tables I and I I . Eighty-two patients
had atrial fibrillation and eight were
in sinus rhythm at the time of their
first embolism.

Systemic embolism occurs frequently in patients with rheumatic heart
disease.^ In addition, the risk of recurrent embolism is greater than for the
first episode.- The incidence of such
recurrence has been reported in various series as 1 9 . 5 % , 3 5 % , ^ and
65%.«
The rate of repeated embolism is
high during the 12 months following
the first embolism.-' 3. >
' In one series^
of 1,017 patients, who were not given
anticoagulants and were observed over
a 20-year period, the recurrence rate
was 9.6% per patient year.
We undertook the present study to
evaluate the effectiveness of long-term
oral anticoagulant therapy in preventing repeated systemic embolism in patients with rheumatic valvular disease.

Cliiucal Observations
Systemic embolism occurred 122
times before anticoagulant therapy was
instituted in this group of patients. The
sites of embolism are shown in Table
I I I . Thirteen patients had their first
embolism after mflral valvulotomy,
three of them in the immediate postoperative period. Of 51 patients who
had cardiac catheterization after first
embolism, 11 had normal hemodynamic findings. In 34, cineangiograms of
the left atrium, carried out at the time
of cardiac catheterization in 34 patients, showed a definite filling defect
suggesting left atrial thrombus in two
patients, and suspected in one.
Of 36 patients who had either closed or open mitral valvulotomy, left

Material
This experience consisted of 90 patients with rheumatic heart disease,
each of whom had a definite history
'Formerly of the Division of Cardiovascular
Diseases, now at the Department of
Medicine, Wayne State University School
of Medicine, Detroit.
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TABLE I
AGE OF THE PATIENTS AT THE TIME OF FIRST EMBOLISM
Age Group

Number of Patients

23-29

3

30-39

10

40-49

28

50-59

37

60 and
above

12

(range 23-74)

TABLE II
NATURE OF VALVULAR LESION
Valvular Lesion

Number of Patients

Mitral Stenosis only

43

Mitral Stenosis and Regurgitation

44

Mitral Regurgitation only

2

Aortic Stenosis only

l
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per patient year in those patients given
adequate doses of anticoagulants.

atrial thrombus was found in eight
patients.
Twenty-one individuals died before completion of this study. The
cause of death is shown in Table I V .
Anticoagulants had been discontinued
in the three patients who died of recurrent systemic embolism.

Complications
Major complications of anticoagulant therapy occurred in seven patients
(Table VI). Such complications are
defined as hemorrhage requiring hospital admission and/or cessation of anticoagulant treatment. Anticoagulants
had been discontinued in two of these
six. There was no mortality because
of bleeding.
Discussion

Anticoagulant Therapy
Treatment with either warfarin or
dicumarol was started in all of these
patients immediately upon hospitalization following systemic embolism.
Dose of the drug was adjusted to keep
the patients' prothrombin time (Quick
one-stage) between 1.6-2 times the
control level. Prothrombin times in
out-patients were measured every three
to four weeks during the follow-up
period as described previously.® The
duration of treatment in this group
ranged between 3-172 months, with an
average of 40.5 months.
During the study period, anticoagulant therapy was discontinued in 12
patients for reasons listed in Table V.
Those who developed recurrent embolism while receiving therapy were
immediately hospitalized and prothrombin time was checked at the
time of admission to see if it was in
the therapeutic range (1.6-2.0 times
control).
Results

These data suggest that adequate
oral anticoagulant therapy is effective
in reducing the risk of recurrent systemic embolism in patients with rheumatic heart disease. Simflar results
have been obtained by other workers
in smafler groups of patients*'
since Wright and Foley introduced this
treatment in 1947." Clearly, absolute
proof of the value of such therapy
would be provided only if a prospective, controlled, randomized study was
made of untreated and treated groups.
In our view such an investigation is
unacceptable for ethical reasons.
The protective value of mitral valvulotomy against systemic embolism is
still debatable. There are reports of
high incidence of embolism after mitral
valvulotomy!!'
yet others indicate
lowered recurrence rates after surgery.!^- " The risk of postoperative
embolism is found to be minimal in
long term follow-up, if anticoagulants
are given. Thus, although anticoagulant therapy should be the treatment
of choice in nonoperated or nonoperable patients, it should also be considered for use after surgery in order to
give added protection against recurrent
systemic embohsm.

Six subjects suffered recurrent systemic embolism while receiving oral
anticoagulant therapy. The average
duration of treatment in this group
was 27 months (a recurrence rate of
1.5% per patient year). Only one of
these six had prothrombin time (Ouick
one-stage) in the therapeutic range at
the time of recurrence. Considering
this fact, the recurrence rate is 0.25%
137

Misra and Schatz

TABLE III
SITE OF SYSTEMIC EMBOLISM BEFORE ANTICOAGULANT THERAPY
Site of Embolism

Number of Patients

Cerebral

68

Peripheral

42

Visceral

12

TABLE IV
CAUSE OF DEATH DURING THE PERIOD OF STUDY
Cause of Death

Number of Patients

Complications of Surgery

7

Congestive Heart Failure

4

Found "dead" in bed
(no autopsy)

5

Recurrent Systemic Embolism

3

Bronchogenic Carcinoma

1

Auto-accident

1
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TABLE V
REASONS FOR THE DISCONTINUATION OF TREATMENT AND ITS OUTCOME
Number of
Patients

Reason for
Stopping Treatment

Follow-up Period
(months)

Recurrence
0

12-50

2 (both died)

3-22

3

2, 31, 48

Post operative
Hemorrhage
Unknown

0
(in Sinus Rhythm)

Post Cardioversion

TABLE VI
COMPLICATIONS OF TREATMENT
No. of
Patients

Complication
Cerebral Hematoma
(Needed Surgical Drainage)

1

Mile Upper Gl Bleeding

2

Menorrhagia

2

Bleeding from Hemorrhoids

2
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